Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells
- 26 July 2010
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 222 (3) , 249-260
- https://doi.org/10.1002/path.2760
Abstract
Endostatin has potent anti‐endothelial and anti‐angiogenic functions. Endostatin was reported to reduce lymphangiogenesis by down‐regulating the level of VEGF‐C in tumour tissues. However, there is little evidence for the direct function of endostatin on lymphangiogenic endothelial cells and lymphangiogenic vessels. Here, we report that cell surface nucleolin, which was reported as an endostatin receptor mediating its anti‐angiogenic and anti‐tumour functions, is also selectively expressed on the cell surface of lymphangiogenic endothelial cells both in vitro and in vivo. Treatment of primary mouse lymphatic endothelial cells (mLECs) by endostatin inhibits mLEC migration, tubule formation, and activation of the Erk pathway in mLECs, while neutralization of cell surface nucleolin or nucleolin knockdown results in loss of the anti‐lymphatic endothelial activities of endostatin. Also, anti‐nucleolin antibody or lentivirus delivered nucleolin siRNA abolishes the anti‐lymphangiogenic function of endostatin in the Matrigel plug assay. Endostatin remarkably inhibits tumour‐associated lymphangiogenesis, leading to reduced lymphatic metastasis. Systemic blockade of nucleolin notably abolishes the anti‐lymphangiogenic and anti‐lymphatic metastatic functions of endostatin. Importantly, endostatin does not affect quiescent lymphatics in normal organs, which is consistent with the lack of expression of cell surface nucleolin in quiescent lymphatics. Taken together, our results demonstrate that endostatin directly acts on lymphangiogenic endothelial cells via cell surface nucleolin, which provides a novel mechanism for the inhibition of tumour lymphangiogenesis and lymphatic metastasis by endostatin. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
Funding Information
- General Programs of the National Natural Science Foundation of China (30771083)
- Major Program of the National Natural Science Foundation of China (30490171)
- National High Technology Research and Development Program of China (2007AA02Z155)
- State Key Development Program for Basic Research of China (2006CB910305)
This publication has 46 references indexed in Scilit:
- Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growthNature Medicine, 2009
- α5β1 Integrin Blockade Inhibits Lymphangiogenesis in Airway InflammationThe American Journal of Pathology, 2009
- Mechanisms of lymphatic metastasis in human colorectal adenocarcinomaThe Journal of Pathology, 2009
- Lymphangiogenesis in gastric carcinoma correlates with prognosisThe Journal of Pathology, 2009
- Tumor and lymph node lymphangiogenesis—impact on cancer metastasisJournal of Leukocyte Biology, 2006
- Targeting lymphangiogenesis to prevent tumour metastasisBritish Journal of Cancer, 2006
- Tumor-Secreted Vascular Endothelial Growth Factor-C Is Necessary for Prostate Cancer Lymphangiogenesis, but Lymphangiogenesis Is Unnecessary for Lymph Node MetastasisCancer Research, 2005
- Focus on lymphangiogenesis in tumor metastasisCancer Cell, 2005
- Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vesselsThe Journal of cell biology, 2003
- Lymphatic Endothelial Tumors Induced by Intraperitoneal Injection of Incomplete Freund's AdjuvantExperimental Cell Research, 1999